Mankind pharma ipo chittorgarh

The Initial Public Offering (IPO) of IKIO Lighting Limited a leading manufacturer of Light Emitting Diode (LED) Lighting in India, was subscribed 66.29 times on the final day of bidding, making it the most subscribed IPO after DCX Systems since Nov 2022. The Qualified institutional buyer portion was the most subscribed with 163.58 times, followed by Non-Institutional portion with 63.35 times and the Retail Portion was subscribed 13.86 times. The IPO received bids of 1,00,92,76,892 shares against the offered 1,52,24,074 equity shares, at a price band of ₹270-285, according to the data available on the stock exchanges. Among all the IPOs made available to the public since Nov 2022, IKIO Lighting witnessed an overwhelmingly positive response across investor categories. The Qualified Institutional Buyer segment recorded a subscription of 163.58 times, followed closely by Kaynes Technology India Ltd at 98.47 times. The Non-institutional segment witnessed a subscription of 63.35 times, with Mankind Pharma trailing closely at 49.16 times. The Retail segment garnered a subscription of 13.86 times, with Archean Chemicals Industries Ltd at 9.96 times. The issue with a face value of Rs 10 per equity share comprising a fresh issue aggregating up to Rs 350 crore, and an offer for sale of up to 9,000,000 equity shares by existing shareholders. The Offer for Sale comprises up to 6,000,000 equity shares by Hardeep Singh, and up to 3,000,000 by Surmeet Kaur (“Selling Shareholders”). Motila...

The Mankind Pharma IPO has begun on 25-Apr-2023. It will close on 27-Apr-2023. The Total IPO Size is 4,326.36 Crore. The company set its IPO price is 1026-1080 Rs Per Share. Basically, there are three basic categories in Mankind Pharma IPO Subscription 1) Qualified Institutional Buyers 2) Non-Institutional Investors 3) Retail Individual Investors (RIIs). Mankind Pharma is established in 1991. Mankind Pharma is Majorly know for it’s Product “Manforce condoms”. Mankind Pharma is a India’s fourth largest pharmaceutical company in terms of Domestic Sales and second largest in terms of sales volume for the Financial Year 2022. They are engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. The 97.60% total revenue comes from the Domestic market. They have created 36 brands in thier pharmaceutical business that have each achieved over ₹500.00 million in FY22. They have several differentiated brands in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories. Table of Contents • • • • • • • • • • • • • • Industry Peers 1) Sun Pharmaceuticals Industries Limited 2) Cipla Limited 3) Zydus Lifesciences Limited 4) Torrent Pharmaceutical Limited 5) Alkem Laboratories 6) JB Chemicals & Pharmaceuticals Limited 7) Eris Lifesciences Limited 8) Eris Lifescience...

BENGALURU, Sept 16 (Reuters) - Indian pharmaceutical company Mankind Pharma Ltd has filed draft papers for an initial public offering (IPO) with the domestic market regulator, according to a prospectus. The IPO will consist of nearly 40.1 million shares on offer for sale from existing shareholders, according to the draft prospectus dated Sept. 15, which did not disclose the total offer size. The IPO will be worth around 55 billion rupees ($689.57 million), a source briefed on the matter told Reuters. The company did not immediately respond to a request for comment. Mankind Pharma, which owned brands such as the Manforce condom and pregnancy testing kit Prega News, had reported a consolidated net profit of 14.33 billion rupees for the year ended March 31, 2022, up 13.3% from the previous year, according to the filing. Consolidated revenue from operations stood at 77.82 billion rupees, compared with 62.14 billion rupees in the previous year. Kotak Mahindra Capital, Axis Capital and J.P. Morgan India were among the book running lead managers to the IPO. ($1 = 79.7600 Indian rupees) About Reuters • About Reuters , opens new tab • Careers , opens new tab • Reuters News Agency , opens new tab • Brand Attribution Guidelines , opens new tab • Reuters Leadership , opens new tab • Reuters Fact Check , opens new tab • Reuters Diversity Report , opens new tab Stay Informed • Download the App , opens new tab • Newsletters , opens new tab Information you can trust Reuters, the news and ...

JPMorgan initiated coverage on the new listing with an overweight rating and a price target of Rs 1,700 per share. The price target implies a potential upside of 15 percent from Monday's closing levels.The firm believes that India’s fourth-largest pharmaceutical company will continue to gain market share, driven by its strong product portfolio and large distribution network.

After muted activity in the primary market in the first quarter of the calendar year 2023, initial public offerings (IPOs) are likely to regain momentum in the current quarter as macro headwinds are easing up.More than 55 companies have received approval from the markets regulator, Securities and Exchange Board of India (SEBI), to raise funds through initial share sale and they are looking to hit Dalal Street and make a splash on stock exchanges. Avalon Technologies, an electronic manufacturing services (EMS) company, has already launched its ₹865 crore IPO on April 3, and the list is going to get longer as the month passes.Among others, Mankind Pharma, SignatureGlobal (India), Northern Arc Capital, Tata Technologies, and Penna Cement Industries are expected to launch their public offer in the April-June quarter of the current fiscal. Mankind Pharma, which manufactures Manforce Condoms and Prega News, is looking to raise around ₹4,200-4,700 crore via IPO route later this month. If succeeded, this would be the biggest IPO in the pharma sector after the ₹6,480 crore public offer by Gland Pharma in November 2020. The IPO comprises an offer for sale (OFS) of 4 crore equity shares by the company's promoters and existing shareholders. Post share sale, shareholding of promoters will decline to 76.50% from 79% at present.The promoters of the company include Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family ...

The initial public offering of Mankind Pharma is likely to open for subscription next week on April 25. The issue can be subscribed till April 27. The company is reported to make its debut at the bourses on May 9, while the anchor books are reported to open on Monday, April 24. Mankind Pharma is India’s fourth-largest pharmaceutical company in terms of domestic sales and second-largest in terms of sales volume for the financial year 2022. According to the red herring prospectus (RHP) of the company, Mankind Pharma's initial stake is entirely an offer-for-sale of up to 4,00,58,844 equity shares with a face value of Re 1 each by its promoters and existing shareholders. Mankind Pharma is reported to cut its issue size as the company is now looking to raise about Rs 4,300-4,350 crore from its primary offering, said some sources. The company was earlier reported to raise about Rs 5,500 crore via primary route Among the promoters, Ramesh Juneja will offload up to 37,05,443 equity shares, while Rajeev Juneja and Sheetal Arora will sell up to 35,05,149 equity shares and 28,04,119 equity shares, respectively. Other shareholders including Cairnhill CIPEF (up to 1,74,05,559 equity shares), Cairnhill CGPE (up to 26,23,863 equity shares), Beige Limited (up to 99,64,711 equity shares) and Link Investment Trust (up to 50,000 equity shares) will also participate in OFS. Being entirely an offer for sale, the net proceeds from the issue will go to the selling shareholders and the company ...